The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference for Patients With Obesity or Overweight: A Systematic Review, Meta-analysis, and Meta-regression of 47 Randomized Controlled Trials
Published version of a preprint
Abstract
OBJECTIVE: To provide an updated synthesis on effects of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) on weight, BMI, and waist circumference incorporating newer randomized controlled trials (RCTs), particularly in individuals with overweight or obesity. RESEARCH DESIGN AND METHODS: We systematically searched PubMed, Embase, and Cochrane Central Register of Controlled Trials (CENTRAL) for RCTs published from inception to 4 October 2024. The search was limited to RCTs evaluating the use of GLP-1 RAs for mean differences from baseline in weight, BMI, and waist circumference in adults with obesity or overweight with or without diabetes. Two independent reviewers performed the literature search and data extraction, resolving disagreements via consensus or third-reviewer consultation. RESULTS: Forty-seven RCTs were included, with a combined cohort of 23,244 patients. GLP-1 RAs demonstrated a mean weight reduction of −4.57 kg (95% CI −5.35 to −3.78), mean BMI reduction of −2.07 kg/m2 (95% CI −2.53 to −1.62), and mean waist circumference reduction of −4.55 cm (95% CI −5.72 to −3.38) compared with placebo. This effect was consistent across diabetes status, GLP-1 RA used, and route of administration. The greatest treatment benefit appeared to favor patients who were younger, female, without diabetes, with higher baseline weight and BMI but lower baseline HbA1c, and treated over a longer duration. Limitations include substantial statistical heterogeneity, in part due to broad inclusion criteria. However, this heterogeneity may improve generalizability by reflecting a wide range of study designs and patient populations. CONCLUSIONS: GLP-1 RAs demonstrated significant weight, BMI, and waist circumference reduction benefits in this meta-analysis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recent literature shows that GLP-1 receptor agonists are highly effective for weight loss and improving metabolic and cardiovascular health, often surpassing the results of lifestyle interventions alone, such as exercise and diet modification.”
From GLP-1 agonists and exercise: the future of lifestyle prioritization (2025) · cites this paper as [6]
In the citing paper
“GLP-1RAs, including liraglutide and semaglutide, can induce substantial weight loss (often 10–15% or more), improve cardiometabolic risk factors, including histological damage associated with metabolic dysfunction–associated steatohepatitis (MASH) (3), and reduce major adverse cardiovascular events in both diabetic and non-diabetic populations (1, 4–12).”
From GLP-1 agonists and exercise: the future of lifestyle prioritization (2025) · cites this paper as [6]
In the citing paper
“GLP-1RAs, including liraglutide and semaglutide, can induce substantial weight loss (often 10–15% or more), improve cardiometabolic risk factors, including histological damage associated with metabolic dysfunction–associated steatohepatitis (MASH) (3), and reduce major adverse cardiovascular events in both diabetic and non-diabetic populations (1, 4–12).”
From GLP-1 agonists and exercise: the future of lifestyle prioritization (2025) · cites this paper as [6]
In the citing paper
“GLP-1RAs consistently demonstrate significant weight loss (mean reductions of 7–9 kg of body weight over a period of about a year) and improvements in BMI, waist circumference, blood pressure, and lipid profiles in both diabetic and non-diabetic populations (5–7, 10, 23).”
From GLP-1 agonists and exercise: the future of lifestyle prioritization (2025) · cites this paper as [6]
In the citing paper
“Current evidence strongly supports the efficacy of GLP-1 receptor agonists for inducing substantial weight loss, improving metabolic control, and reducing cardiovascular risk – often surpassing the short-term effects of exercise alone (4–10, 23).”
From GLP-1 agonists and exercise: the future of lifestyle prioritization (2025) · cites this paper as [6]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
Murray, C. J. L., Aravkin, A. Y., Zheng, P., Abbafati, C., Abbas, K. M., Abbasi-Kangevari, M., Abd-Allah, F., Abdelalim, A., Abdollahi, M., Abdollahpour, I., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30752-2 · Cited by 9,854
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J., Bossuyt, P., Boutron, I., Hoffmann, T., mulrow, C., Shamseer, L., Tetzlaff, J., Akl, E., Brennan, S. E., et al. (2020) · doi:10.31222/osf.io/v7gm2 · Cited by 5,177
Hubert, H. B., Feinleib, M., McNamara, P. M., & Castelli, W. P. (1983) · Circulation · doi:10.1161/01.cir.67.5.968 · Cited by 4,241
Guh, D. P., Zhang, W., Bansback, N., Amarsi, Z., Birmingham, C. L., & Anis, A. H. (2009) · BMC Public Health · doi:10.1186/1471-2458-9-88 · Cited by 3,855
Obesity and cardiovascular disease: a scientific statement from the American Heart Association
Powell-Wiley, T. M., Poirier, P., Burke, L. E., Després, J.-P., Gordon-Larsen, P., Lavie, C. J., Lear, S. A., Ndumele, C. E., Neeland, I. J., Sanders, P., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000973 · Cited by 3,691
GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology
Guyatt, G. H., Oxman, A. D., Schünemann, H. J., Tugwell, P., & Knottnerus, A. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.09.011 · Cited by 3,094
Methley, A. M., Campbell, S., Chew-Graham, C., McNally, R., & Cheraghi-Sohi, S. (2014) · BMC Health Services Research · doi:10.1186/s12913-014-0579-0 · Cited by 2,706
Weight gain as a risk factor for clinical diabetes mellitus in women
Colditz, G. A., Willett, W. C., Rotnitzky, A., & Manson, J. E. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-7-199504010-00001 · Cited by 2,064
Waist circumference and not body mass index explains obesity-related health risk
Janssen, I., Katzmarzyk, P. T., & Ross, R. (2004) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/79.3.379 · Cited by 2,013
Sattar, N., Lee, M. M. Y., Kristensen, S. L., Branch, K. R. H., Del Prato, S., Khurmi, N. S., Lam, C. S. P., Lopes, R. D., McMurray, J. J. V., Pratley, R. E., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00203-5 · Cited by 1,599
Self-citationEffects of Obesity on Pharmacokinetics: Implications for Drug Therapy
Cheymol, G. (2000) · Clinical Pharmacokinetics · doi:10.2165/00003088-200039030-00004 · Cited by 631
SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
Brown, E., Heerspink, H. J. L., Cuthbertson, D. J., & Wilding, J. P. H. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00536-5 · Cited by 581
Filippatos, T. D., Panagiotopoulou, T. V., & Elisaf, M. S. (2014) · The Review of Diabetic Studies · Cited by 560
Yao, H., Zhang, A., Li, D., Wu, Y., Wang, C.-Z., Wan, J.-Y., & Yuan, C.-S. (2024) · BMJ · doi:10.1136/bmj-2023-076410 · Cited by 558
Emerging role of GLP-1 agonists in obesity: A comprehensive review of randomised controlled trials
Popoviciu, M.-S., Păduraru, L., Yahya, G., Metwally, K., & Cavalu, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310449 · Cited by 280
The Importance of Waist Circumference in the Definition of Metabolic Syndrome
Katzmarzyk, P. T., Janssen, I., Ross, R., Church, T. S., & Blair, S. N. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1636 · Cited by 273
Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity
Maselli, D. B., & Camilleri, M. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/5584_2020_496 · Cited by 248
Differential GLP-1R Binding and Activation by Peptide and Non-peptide Agonists
Zhang, X., Belousoff, M. J., Zhao, P., Kooistra, A. J., Truong, T. T., Ang, S. Y., Underwood, C. R., Egebjerg, T., Šenel, P., Stewart, G. D., et al. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.09.020 · Cited by 222
Jensen, S. B. K., Blond, M. B., Sandsdal, R. M., Olsen, L. M., Juhl, C. R., Lundgren, J. R., Janus, C., Stallknecht, B. M., Holst, J. J., Madsbad, S., et al. (2024) · eClinicalMedicine · doi:10.1016/j.eclinm.2024.102475 · Cited by 207
Geissbühler, M., Hincapié, C. A., Aghlmandi, S., Zwahlen, M., Jüni, P., & da Costa, B. R. (2021) · BMC Medical Research Methodology · doi:10.1186/s12874-021-01310-0 · Cited by 195
Obesity and chronic kidney disease: A current review
Nawaz, S., Chinnadurai, R., Al‐Chalabi, S., Evans, P., Kalra, P. A., Syed, A. A., & Sinha, S. (2022) · Obesity Science & Practice · doi:10.1002/osp4.629 · Cited by 168
Gadekar, T., Dudeja, P., Basu, I., Vashisht, S., & Mukherji, S. (2018) · Medical Journal Armed Forces India · doi:10.1016/j.mjafi.2017.12.001 · Cited by 167
A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes
Andersen, A., Knop, F. K., & Vilsbøll, T. (2021) · Drugs · doi:10.1007/s40265-021-01499-w · Cited by 160
User’s guide to mechanism of action and clinical use of GLP-1 receptor agonists
Shaefer, C. F., Kushner, P., & Aguilar, R. (2015) · Postgraduate Medicine · doi:10.1080/00325481.2015.1090295 · Cited by 128
Adverse drug reactions in the elderly
Brahma, D. K., Wahlang, J. B., Marak, M. D., & Sangma, M. C. (2013) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.4103/0976-500x.110872 · Cited by 125
Diet and Exercise for Weight Loss: A Review of Current Issues
Volek, J. S., VanHeest, J. L., & Forsythe, C. E. (2005) · Sports Medicine · doi:10.2165/00007256-200535010-00001 · Cited by 114
Metabolic and cardiovascular benefits of GLP‑1 agonists, besides the hypoglycemic effect (Review)
Iorga, R., Bacalbașa, N., Carşote, M., Bratu, O. G., Stănescu, A. M. A., BUNGAU, S. G., Pantiș, C., & Diaconu, C. C. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.8714 · Cited by 103
A Role for GLP-1 in Treating Hyperphagia and Obesity
Grill, H. J. (2020) · Endocrinology · doi:10.1210/endocr/bqaa093 · Cited by 101
Gastrointestinal motility disorders in patients with diabetes mellitus
Abrahamsson, H. (1995) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1995.tb01194.x · Cited by 92
Thomas, M. C., Coughlan, M. T., & Cooper, M. E. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.01.004 · Cited by 68
Potential Roles of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) in Nondiabetic Populations
Xu, D., Nair, A., Sigston, C., Ho, C. L. B., Li, J., Yang, D.-Y. D., Liao, X., Chen, W., Kuang, M., Li, Y., et al. (2022) · Cardiovascular Therapeutics · doi:10.1155/2022/6820377 · Cited by 61
Chubb, B., Gupta, P., Gupta, J., Nuhoho, S., Kallenbach, K., & Orme, M. E. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01034-w · Cited by 41
Dutta, D., Nagendra, L., Anne, B., Kumar, M., Sharma, M., & Kamrul‐Hasan, A. B. M. (2024) · Obesity Science & Practice · doi:10.1002/osp4.743 · Cited by 35
Wong, S. Y., Lee, A. R. Y. B., Sia, A. H. J., Wo, Y. J., Teo, Y. H., Teo, Y. N., Syn, N. L. X., Ong, C. C., Teo, L., Yeo, T., et al. (2022) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-022-07360-w · Cited by 30
Self-citationFeng, Z., Tong, W. K., Zhang, X., & Tang, Z. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1226778 · Cited by 13
Gluud, L. L. (2023) · American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2023.07.007 · Cited by 6
Research works printed but not linked: 2
- World Health Organization, 2000, The Asia-Pacific Perspective: Redefining Obesity and Its Treatment.
- Higgins, 2023, Cochrane Handbook for Systematic Reviews of Interventions Version 6.4.
Cited by
Obesity Treatment With Bariatric Surgery vs GLP-1 Receptor Agonists
Barrett, T. S., Hafermann, J. O., Richards, S., LeJeune, K., & Eid, G. M. (2025) · JAMA Surgery · doi:10.1001/jamasurg.2025.3590 · Cited by 87
Ndumele, C. E., Rodríguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M. S., Bangalore, S., Bozkurt, B., Breathett, K. K., Clarke, S. L., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001453 · Cited by 146
Glucagon-like peptide-1 receptor agonists and muscle mass effects
Ceasovschih, A., Asaftei, A., Lupo, M. G., Kotlyarov, S., Bartušková, H., Balta, A., Sorodoc, V., Sorodoc, L., & Banach, M. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107927 · Cited by 64
Ndumele, C. E., Rodriguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M., Bangalore, S., Bozkurt, B., Breathett, K., Clarke, S. L., et al. (2026) · JACC · doi:10.1016/j.jacc.2026.03.056 · Cited by 90
GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension
Sioutas, G. S., Mualem, W., Reavey-Cantwell, J. F., & Rivet, D. J. (2025) · JAMA Neurology · doi:10.1001/jamaneurol.2025.2020 · Cited by 54
Metadata
- Authors
- Wong, H. J., Sim, B., Teo, Y. H., Teo, Y. N., Chan, M. Y., Yeo, L. L. L., Eng, P. C., Tan, B. Y. Q., Sattar, N., Dalakoti, M., & Sia, C.-H.
- Affiliations
- National University of Singapore (SG)
- National University Heart Centre Singapore (SG)
- National University Hospital (SG)
- University of Glasgow (GB)
- Corresponding author
- Sia, Ching-Hui
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2025-01-22
- Volume
- 48
- Issue
- 2
- Pages
- 292-300
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W4406726472
- Semantic Scholar
- 78bb0c3810a832316cd3e039722f8764a2c24747
- Cited by
- 208
- References
- 38
- Citations by year
- 2026: 136 · 2025: 72
- FWCI
- 28.23
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novartis (Writing support)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- GLP-1 receptor agonists, obesity, overweight, weight loss, body mass index, waist circumference, diabetes mellitus, treatment effect modifiers, HbA1c, route of administration
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Female, Humans, Hypoglycemic Agents, Obesity, Weight Loss, Body Mass Index, Randomized Controlled Trials as Topic, Overweight, Waist Circumference
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.